Inventory doesn't equate to finished goods - it could very well be a stockpile of sugar used throughout the year. Also R&D awards might not be so smooth going forward. I'll still hope for 19 mil, but i'm not overly confident that they'll beat it.
Last q, $6 mil of the company's product revenue was derived from Algenist/Everdeep and $6.9 mil was R&D. This means that only $3 mil was from Clinton/Peoria.
Hoping R&D stays similar and assuming Algenist is near the same, you'd have to double Clinton sales or improve the product mix - a difficult task if the production output was only up about 40% over the quarter.. Algavia is now selling at Peoria, so that might help. R&D revenue is a wild card also. And of course, Algenist could have a stellar quarter.. But all said, I'll be happy if they hit $19 rather than expecting a beat.
I am more hopeful of news of a different kind though in the form of partnerships.
maybe trademarked, but not patented. This is also the 2nd extension which was granted as its been filed for some time, dating back to 2012. good to see they haven't abandoned this though. definitely want to see more advances in the biomass.
Nah, they bought one & decided to go elsewhere. It just didn't meet their needs. Gair et al initiated their hate campaign not long after.
A/R typically converts to cash over a 90-day period, and there should almost always be some kind of a balance in this accounting category unless revenues stopped altogether or unless companies immediately paid their accounts payable (which doesn't happen often).
If revenue stagnates even as A/R continues to increase, that is typically a bad sign as it means the company isn't collecting on the payments it's owed.. However, in a sales- growth environment (such as what Solazyme is enterring into) one would expect A/R to also increase. This is a normal part of any business..
I really want a biomass update. Where is all the biomass going? Even if they just merely say its going to R&D right now and dont expect sales on it anytime soon. No coproduct revenue has really been accounted for yet and it would really help to suggest that it's there.......considering that we know it is.
I also want some slight details on production volumes and ASPs. (9 months is a bit long IMO to be working through your 2013 inventory if they use that "some of the costs were allocated to R&D" statement again).
I agree on $19 mil + & color on Clinton.
I also could do without an update on Moema as long as they make some effort to suggest downstream integration is part of the 12-18 month expectation
$250 mil in cash on hand is unlikely imo, and I'll be happy with $240. I expect loss will increase as Moema ramps, but would like for the Operating loss on the income statement (which only really accounts for Clinton/Peoria) to stay similar to current quarter or begin to trend down like it did ever so slightly in the last quarter.
I think your understanding of accounts receivable is a bit off. A/R is revenue already accounted for but the cash hasn't come in yet.
tells me that it's definitely not one of you placing those orders... unless someone has a knack for a lot of decimal places.
You already mentioned them in your first comment. Unless we're counting aliases instead of people.
long-term, its the most abundant volume market. who knows what a blend will sell for (i doubt $3000/MT), but the attractiveness is the long-term market. Surrendering biofuels now would be a step in the wrong direction rather than creating a trail of proven capabilities for future clients to follow.
In defense of today's action, it's not like the last few months made much sense either. Thank your local hedge fund for the irrationality.
"Accounts receivables and unbilled revenues increased due primarily to the commercial launch of Encapso ™ lubricant, Tailored ™ oils and fuel blends and timing of payments received under our R&D
AR/UR should increase as sales ramp. That's normal. But it is nice to have more cash flowing over time.
75 potential customers have already been sampling.... that's where your one box/tote comes in. Once you're a real customer, the volume surely goes up a notch.
despite Jim Lane's assertion that these "4th-gen" companies hold much promise, it'll really be dependent upon the 3rd gen (SZYM) and possibly the 2nd gen companies to make sure the moneys there for them when it comes to raising the capital needed for a roll-out of their plants.
fermentalg has a loooong way to go still. Heck, according to its road map it doesn't even plan to put out its first cosmetic/pharma product until 3 years from now. Thats where we were at our IPO back in 2011.
"These and other developments will be discussed on Solazyme’s investor conference call...."
Like they would reveal everything to you now. Just be sure to lock in those short profits of yours before the CC.